New-onset chronic and neuropathic pain in survivors of severe COVID-19: A secondary analysis of the PAIN-COVID Trial.

New-onset chronic and neuropathic pain in survivors of severe COVID-19: A secondary analysis of the PAIN-COVID Trial.

Publication date: Sep 23, 2025

Survivors of critical illnesses, including COVID-19, are at risk of developing Chronic ICU-Related Pain (CIRP) and neuropathic pain (NP). This study evaluates the incidence of CIRP and NP 6 months after hospital discharge and their impact on pain intensity, functional status, and quality of life (QoL). We performed an observational prospective cohort analysis based on a secondary analysis of data from the existing PAIN-COVID randomized controlled trial, which included adult survivors of severe COVID-19 admitted to the ICU. CIRP and NP were assessed at 6 months post-discharge using validated scales (Brief Pain Inventory [BPI] and DN4-interview). Propensity score matching was used to control for confounding factors when comparing pain intensity, functional impact, and QoL between groups. New-onset CIRP was reported by 47. 7% of patients. In matched cohorts, patients with CIRP had significantly lower EQ-5D-5 L index (0. 705 [0. 613-0. 818]; p 

Concepts Keywords
Covid Calidad de vida
Hospital Chronic Pain
Months COVID-19
Reanim Critical Illness
Severe Dolor crónico
Dolor neuropático
Enfermedad crítica
Neuropathic Pain
Quality of Life
Supervivientes
Survivors

Semantics

Type Source Name
disease MESH neuropathic pain
disease MESH COVID-19
disease MESH critical illnesses
disease MESH functional status
disease IDO quality
disease MESH Long Covid
disease MESH Chronic Pain

Original Article

(Visited 11 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *